News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

Roberts & Ryan Inc. Joins NYSE and Welcomes the Mark J. Muller Equities Team to Strengthen Its Equity Trading Operations.

Roberts & Ryan, Inc.

Roberts & Ryan Inc., a Veteran Owned broker-dealer, is delighted to announce it has been approved for membership by the New York Stock Exchange and began operating today on the iconic NYSE trading floor. In conjunction with this milestone, the firm proudly introduces the esteemed Mark J. Muller Equities trading team to its floor operation. Comprising seasoned professionals including Mark Muller and Robert Moran, the team brings a wealth of experience and expertise to Roberts & Ryan Inc. The addition of the Mark J. Muller Equities trading team to the firm's already robust equity trading platform serves to fortify Roberts & Ryan's capabilities, reinforcing the company's commitment to anticipating and addressing client needs and concerns. Membership at the NYSE will empower the firm to harness broader liquidity pools, achieve parity in situational trading, and access real-time insights from point-of-sale access. These synergies, combined with Roberts & Ryan's existing institutional trading operation, will enhance the company's ability to serve equity clients effectively. Additionally, Roberts & Ryan will be well-positioned to assist clients during key price discovery events on the NYSE Floor, such as IPOs and secondary offerings. Founded on the core value of prioritizing competence, Roberts & Ryan Inc. places client satisfaction at the forefront of its operations. As a Veteran-Owned firm with the requisite certifications to fulfill all DEI mandates and set-asides, the company is dedicated to its social mission. A portion of all commission dollars earned is donated to foundations supporting Veterans and other deserving charities. Since 2018, this initiative has generated over $1.8 million in charitable contributions, benefiting more than 800 Veterans and their families. The combination of competency, diversity, and charity has enabled Roberts & Ryan Inc. to make a meaningful impact in the community. When asked to share his thoughts, Mark Muller, Managing Director of Roberts & Ryan's NYSE Floor Operations, remarked, "The Muller team is excited to be part of the Roberts & Ryan family, a firm that not only provides great service to its clients, but also supports our nation's Veterans and disadvantaged young adults. With our shared vision and commitment to excellence, we will continue to provide value-added executions from the floor of the NYSE." "With these strategic developments, Roberts & Ryan Inc. is poised to deliver enhanced services and value to our clients while upholding our commitment to excellence, integrity, and social responsibility," said Edward D'Alessandro, Chief Executive Officer of Roberts & Ryan, Inc. About Roberts and Ryan, Inc. Roberts & Ryan, Inc. is a Service-Disabled Veteran Owned (SDVO) broker-dealer with execution capabilities in the capital markets, equities, and fixed-income trading. The firm was founded in 1987 by a United States Marine Corps Vietnam combat veteran and Purple Heart recipient. With over $1.8 million in committed donations, Roberts & Ryan is active in donating to charitable foundations that make significant positive impacts in the lives of Veterans and their families, focusing primarily on general wellness, mental health, and career transition. To learn more about Roberts & Ryan, please visit www.roberts-ryan.com. Contact Details Roberts & Ryan, Inc. Sadie Millard, Chief Administrative Officer +1 646-542-0012 smillard@roberts-ryan.com Company Website https://www.roberts-ryan.com

March 04, 2024 12:00 PM Eastern Standard Time

Image
Article thumbnail News Release

Centre for Neuro Skills Study Finds Differences in Sleep Patterns Between Men and Women with Post-Traumatic Brain Injury

Centre for Neuro Skills

Centre for Neuro Skills (CNS), a premier provider of traumatic and acquired brain injury rehabilitation services, has shared findings from a study researching sleep-wake disturbances, published in Neurotrauma Reports on January 3, 2024. They found that sleep deficits are correlated with poorer brain injury patient outcomes (verbal skills, depression issues), as monitored by therapists and administrators at CNS. The study included data from 57 individuals between the ages of 18-70 who sustained traumatic brain injuries (TBIs). CNS collected the data between 2018-2020 at its in-house sleep centers in Dallas and Bakersfield. “Overall, we found that lack of REM sleep negatively impacts memory and learning for TBI patients,” says Dr. Stefanie Howell, a neuroscientist at CNS. “In research, we must also consider additional variables that may impact our results. This includes biological variables such as sex, as biological sex does impact sleep. Our research found that women achieve REM sleep far less than men. Additionally, a decrease in REM sleep was associated with poorer learning and memory task performance, indicating a potential impact on outcome and recovery.” In addition to biological sex, CNS evaluated several sleep medications to determine if their use impacted sleep for TBI patients. Howell said “medications do not seem to be impacting results between men and women; however, the use of melatonin was associated with improved REM sleep and may therefore be of potential short-term benefit to TBI patients. It is important to note that over-the-counter melatonin options are variable due to formula ingredients.” “Through research, we’ve found that while sleep supplements in the benzodiazepine family may cause someone to fall asleep, they suppress REM sleep, which is crucial for memory recollection and improved learning,” says Dr. Brent Masel, executive vice president of medical affairs at CNS. “Melatonin was found to help improve REM sleep in the short term, but it’s important to note that long-term use can be habit-forming. I cannot stress this enough – the best medication is no medication.” In 2021, CNS published two other studies regarding sleep-wake disturbances post-stroke. The first evaluated the incidence of obstructive sleep apnea (OSA) and the second study considered the anatomical location of the injury (stroke). *** About Centre for Neuro Skills Centre for Neuro Skills is an experienced and respected world leader in providing intensive rehabilitation and medical programs for those recovering from all types of brain injury. CNS covers a full spectrum of advanced care from residential and assisted living to outpatient/day treatment. Founded by Dr. Mark Ashley in 1980, CNS has seven locations in California and Texas. For more information about Centre for Neuro Skills, visit: www.neuroskills.com, Facebook, Twitter, LinkedIn, YouTube. Media, please note: Visual assets, including photos, are available. To request an interview with CNS leadership or clinical staff, please contact Robin Carr at 415.766.0927 or CNS@landispr.com. # # # Contact Details Landis Communications Inc. Robin Carr +1 415-766-0927 cns@landispr.com Company Website https://www.neuroskills.com/

March 04, 2024 08:01 AM Pacific Standard Time

Image
Article thumbnail News Release

MicroSalt revolutionises salt intake with low sodium technology and big growth plans

MicroSalt PLC

MicroSalt PLC (AIM: SALT) CEO Rick Guiney tells Proactive's Stephen Gunnion that the recently listed company specialises in innovative food technology that enhances the flavour of salt with significantly less sodium through patented technology. This technology changes the salt crystal's size, increasing its surface area for a fuller flavour without excess sodium intake, a major global health concern. The company targets food manufacturers, offering a product with the same functionality as traditional salt but processed differently. Additionally, MicroSalt aims to enter consumer markets, with products already available on Amazon in the UK and in about 500 stores in the US. MicroSalt's technology is distinguished by an exclusive patent, marking a significant advancement in efforts to reduce sodium consumption over the past two decades. The company's strategy includes expanding into the UK retail market, engaging with major supermarket groups to offer MicroSalt on shelves and incorporate it into their own brands, aiming for products like crisps to retain their taste while having 50% less sodium. The decision to list on the AIM market reflects London's receptivity to small food technology firms and its strategic importance in the food and ingredients sector. MicroSalt's IPO aims to raise public awareness about its low-sodium solution and the broader health issues related to sodium intake. Regulatory support for low sodium initiatives is significant, with governments recognizing the health and economic benefits of reducing sodium consumption. MicroSalt has also announced an export collaboration with American Trading International (ATI), facilitating access to 90 markets through ATI's distribution network, and enhancing the company's growth prospects. Looking ahead, MicroSalt anticipates significant developments in 2024 and 2025 as it expands its reach to consumers and large food manufacturers. Contact Details Proactive UK Proactive UK +44 20 7989 0813 UKEditorial@proactiveinvestors.com

March 04, 2024 08:47 AM Eastern Standard Time

Video
Article thumbnail News Release

No More Jitters? Company Says Its Hydro-CaffeineTM Improves Your Morning Caffeine Fix’s Benefits By 400-500%

Rexis Biotech

By Meg Flippin, Benzinga It’s no secret that many people turn to chugging caffeine-induced drinks to get them through the day. But what they may not realize is too much caffeine can be a bad thing. Jitters, elevated heart rates and anxiety are just some of the side effects many consumers just learn to accept. But caffeine overload doesn’t have to be the foregone conclusion just to get your caffeine fix. Products like Rexis Biotech Inc.’s Hydro-Caffeine TM are revolutionizing the energy drink market. Thanks to its nanotechnology, the Delaware biotech firm says it has created a better caffeine that gives you energy without all the bad side effects. Quadruple The Effects For Less Hydro-Caffeine can be found in Rexis’s new groundbreaking energy drink Squared Energy, a product line extension to their already successful Squared brand which is available in over 2,000+ retailers in 10 states across the country. It is created using the company’s proprietary co-crystal that amplifies the effects by increasing the bioavailability of its caffeine co-crystal by four to five times. Rexis is taking it up a level with this drink by fusing Hydro-Caffeine with naturally occurring Hemp Delta-9 THC + broad-spectrum CBD to create a singular polymorph molecule in which all three work together for the ultimate entourage effect. That creates a unique experience for consumers highlighted by clear-headed, focused energy without any jitters or anxiety, according to Rexis. The first two flavors they’ll be bringing to market include a Raspberry Lemonade and their High Spirits Awards-winning Sparkling Grapefruit. Hydro-Caffeine could be a huge winner for both consumers and Rexis shareholders; caffeine is a very popular energy stimulant. Not only does caffeine give you energy but it can reduce the risk of cardiovascular disease and type 2 diabetes and improve longevity, which is why caffeine is so popular in the U.S. and abroad. While coffee and tea are the most common ways to get a caffeine fix, energy drinks, caffeine pills and supplements are also popular. In fact, the global energy drinks market is poised to reach $108.4 billion by 2031, growing at a CAGR of 8.2% from 2022 to 2031. In the U.S. 93% of Americans say they consume caffeine, with 75% partaking in it daily, according to the International Food Information Council. One-quarter of that group consumes caffeine three or more times a day. It is the latter group that worries doctors. Caffeine overdose is real and can lead to several issues including insomnia, jitters, anxiety, elevated heart rate and headaches. It tends to happen a lot since many Americans underestimate the safe amount of caffeine to consume and still remain healthy. Worse, the International Food Information Council found nearly 29% of consumers in the U.S. say they don’t know what the safe amount of caffeine is. The Secret Sauce Rexis says that with Squared Energy, you need not worry about getting too much or too little caffeine to reap the benefits. The secret behind it is the Hydro-Caffeine fibers which are absorbed more efficiently and rapidly through sublingual and buccal absorption in the cheeks and mouth. That differs from traditional energy drinks, which use a form of encapsulated caffeine in which the caffeine is coated with a sugar-type substance to eliminate bitter flavors. That process increases the time it takes to absorb, decreasing the portion introduced into circulation. The caffeine then must be processed by first-pass metabolism, which reduces efficacy even more. As a result, Rexis says you may receive as much as 25% less of the ingredient in your system than what is said on the packaging. “Shaking Up” The Market Rexis’s potentially game-changing Squared Energy drink isn’t the only way the biotech is shaking up the consumer markets. With its proprietary nanotechnology, it can improve the potency, taste and speed of effectiveness in everything from energy drinks to cannabis-infused beverages. The goal of Rexis Biotech is to be the Nvidia Corp. (NASDAQ: NVDA) or Intel Corp. (NASDAQ: INTC) of the consumer packaged goods industry. It envisions a world where brands license Rexis’s nanotechnology to enhance everything from drinks to food. To meet that end Rexis also manufactures and distributes products for companies including Hemp D9 beverages for 3Chi and functional mushrooms for First Person. It also licenses its technology to brands in the regulated cannabis market including Smokiez and Happy Valley. Caffeine will always be a preferred way to get a boost, but that doesn’t mean consumers have to accept the negative side effects. Jitters, headaches and elevated heart rates could become a thing of the past thanks to Rexis Biotech. Rexis Biotech is currently raising funds to support its growth. Click here to learn more about Rexis Biotech’s crowdfunding raise, and how to invest in the company the founders are modeling after Nvidia! Featured photo by Mark Daynes on Unsplash. Rexis is the industry leader and pioneer in developing Hydrophobic Molecule Delivery systems. Leading in the innovation, production and formulation of water based ingredients for use in the Pharmaceutical and Consumer Packaged goods industry. Established in 2022, Rexis is building a core mix of proprietary IP used to sustain strong sales models with pharmaceutical licensees, consumer packaged goods manufacturers and clinical research teams. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Ryan Erving ryan@rexissystems.com Company Website https://www.rexissystems.com

March 04, 2024 08:25 AM Eastern Standard Time

Image
Article thumbnail News Release

Jewish News Syndicate Commentary: Anti-Defamation League ‘Smeared’ NLPC

NLPC

Elle Krasne-Cohen has come to the defense of National Legal and Policy Center in an opinion piece distributed by the Jewish News Service titled, “When Will the ADL Start Fighting Antisemitism on the Left?” She points to the Anti-Defamation League’s embrace of causes like Black Lives Matter and juxtaposes it with an incident closer to home for NLPC: More recently, the ADL smeared two mainstream policy organizations—the National Center for Public Policy Research (NCPPR) and the National Legal and Policy Center (NLPC)—accusing them without evidence of antisemitism. The ADL claimed that mere criticism of “globalism” or “globalist organizations,” including the antisemitic United Nations, is an “antisemitic dog whistle.” Krasne-Cohen continues: The NCPPR and NLPC are mainstream organizations, neither of which, to my knowledge, has displayed antipathy towards Jews or any other racial or religious minority. The smear was in the form of a posting on the ADL website on November 21 titled “Conspiracy Theories, Some With Antisemitic Roots, Crop Up in 2023 Shareholder Proposals.” The post appeared only six weeks after the October 7 Hamas terrorist attack, while antisemitic incidents and demonstrations were exploding worldwide. Why the ADL would devote time and resources to attacking NLPC, which has a long history of fighting antisemitism, was completely baffling to us. Equally baffling, the hit piece was dropped as the Thanksgiving holiday was getting underway. It was almost as if the ADL wanted the story out but didn’t want anyone to report it. The strategy, if it existed, worked because no one else covered it. Even more weirdly, the post itself carried this all-purpose disclaimer that tended to negate the impression that every other word of the post was calculated to create: At this time, there is no evidence to suggest that either organization’s agents espouse overt antisemitism, or that these proposals were filed with antisemitic intentions. So what is going on here? What was behind the attempted smear of NLPC and our ally, the National Center for Public Policy Research? Could it be that the ADL just doesn’t like us filing shareholder proposals, a form of activism dominated for many years by the Left? Krasne-Cohen and a number of other Jewish commentators and activists are making this case that the ADL, under the “leadership” of former Obama White House staffer Jonathan Greenblatt, has devolved into an ideological and partisan tool. ADL’s hit and run on NLPC was actually quite clever. Even if no one paid any attention to it when it was published, whoever wrote it (the piece is unsigned) sought to plant it on the internet for anyone to find for years to come. Any journalist seeking to discredit us can now simply describe NLPC as a “group that, according to the ADL, promotes antisemitic conspiracy theories.” It was a nice try but it is not going to work. NLPC’s track record of fighting antisemitism over many years is just too strong. Indeed, while the ADL has been sanitizing antisemitism by partnering with the likes of Al Sharpton, NLPC has been consistent, resolute and effective. To wit: Ben & Jerry’s - When the Unilever subsidiary Ben and Jerry’s announced in 2021 that it would end ice cream sales in “Occupied Palestinian Territory,” NLPC swung into action, launching the StopBenandJerrys.org website. In September 2021, NLPC filed a Complaint with the Internal Revenue Service (IRS) against Anuradha Mittal, the anti-Israel chair of the Ben & Jerry’s board of directors. A few weeks later, she was named 2021 “Antisemite of the Year” by the website StopAntisemitism.org. Mittal appeared to have violated laws governing self-dealing by acting as a trustee of the Ben & Jerry’s Foundation while approving donations to her personal nonprofit where she is executive director taking a full-time salary. Also, the president of Ben & Jerry’s charitable foundation, Jeff Furman, steered more than $100,000 of its funds to his own nonprofit organization. In the wake of October 7 Hamas attack, Flaherty wrote an op-ed titled, “Unilever, Ice Cream and Antisemitism.” Unilever Divestment - NLPC was a proponent of Unilever divestment efforts in New York, New Jersey, North Carolina and Virginia. From the September 16, 2021, New York Times: “We are doing this because somebody has to hold the independent board of Ben & Jerry’s accountable for their anti-Semitic use of their platform and company resources,” said Tom Anderson, a director of the National Legal and Policy Center. NLPC collaborated with activist investor Michael Asher in support of Unilever divestment by New York State and New York City. In Virginia, Flaherty met with State Attorney General Jason Miyares and urged him to seek divestment of state funds from Unilever. In North Carolina, NLPC asked Treasurer Dale Folwell requesting divestiture of Unilever holdings in public pension funds. Black Lives Matter & Patrisse Cullors - As a result of original NLPC research, Black Lives Matter Global Network Foundation co-founder Patrisse Cullors was forced to resign from the group in 2021. NLPC’s allegations, detailed in a Complaint to the IRS, related to her purchase of four pieces of real estate, and apparent self-dealing and inurnment. NLPC has also emphasized Cullors’ 2015 call at Harvard Law School for individuals to “step up boldly and courageously to end the imperialist project that’s called Israel.” NLPC was early in reporting about Black Lives Matter’s (BLM) links to anti-Israel groups. In 2016, Carl Horowitz, then a member of the NLPC staff, wrote a website post titled “Black Lives Matter Activists Join Anti-Israel Boycott.” Following October 7, NLPC asked Visa, Inc. to remove its BLM endorsement from its website and condemn Hamas and antisemitism. We had raised the BLM issue earlier in the year at the company’s shareholders’ meeting. NLPC had also raised the issue of Coca-Cola’s support for BLM at the company’s annual meeting. ADL’s Omar Resolution - NLPC has been a persistent critic of Reps. Alexandria Ocasio-Cortez, Ilhan Omar, and Rashida Talib. While we have cited financial irregularities in a Federal Election Commission complaint against Ocasio-Cortez and a House Ethics Committee complaint against Omar, NLPC has also criticized hostility to Jews by these members. In 2019, NLPC endorsed and publicized the ADL-initiated House resolution condemning Omar. See this op-ed titled “Antisemitism and Islamophobia: No Moral Equivalence” by Horowitz. Foreign Funding of U.S. Higher Education - The recent spate of on-campus antisemitic incidents has shed light an issue on foreign financial support for American colleges and universities, an issue that NLPC has investigated and publicized for several years. See this column by Charles Gasparino that extensively quotes NLPC Counsel Paul Kamenar. Al Sharpton - Whereas the present leadership of the ADL has sought to erase Sharpton’s past, NLPC will not forget his incitements in the 1991 Crown Heights riots, in which a Jew was murdered, nor will we forgive his dangerous statements, such as “If the Jews want to get it on, tell them to pin their yarmulkes back and come over to my house.” Sharpton was fined $285,000 in 2005 by the Federal Election Commission as a result of an NLPC Complaint for running an “off the books” presidential campaign. For several years, NLPC raised the issue of support for Sharpton’s National Action Network (NAN) at the shareholders’ meetings of American corporations, including PepsiCo, Anheuser-Busch and Colgate-Palmolive. Unlike the ADL, NLPC has never used the fight against antisemitism as a partisan weapon. In 2010, NLPC objected to the sponsorship of Sharpton’s National Action Network annual meeting by the Republican National Committee (RNC) and the participation of then-RNC Chairman Michael Steele. In 2009, NLPC asked former House Speaker Newt Gingrich to end his partnership with Sharpton in a campaign for “education reform.” That same year, NLPC criticized then-President George W. Bush for praising Sharpton. Jesse Jackson - In 2005, the New York Stock Exchange ended its financial support for Jackson’s Citizenship Education Fund, in response to a demand by NLPC that cited Jackson’s 1984 “hymie” and “Hymietown” comments, as well as financial improprieties involving the Fund. And if none of this is good enough for the ADL, it should be noted that NLPC has many Jewish supporters, including prominent individuals and former government officials, several of whom serve on the boards of local and national Jewish organizations. From 2001 to the time of his death in 2019, Edward M. Ackerman of Dallas was a key advisor and major donor to NLPC. His legacy is carried on today by NLPC and the Ackerman Center for Holocaust Studies at the University of Texas at Dallas. The ADL itself has partnered with the Ackerman Center. Founded in 1991, the National Legal and Policy Center promotes ethics in public life through research, investigation, education and legal action. Contact Details National Legal and Policy Center Dan Rene +1 202-329-8357 drene@nlpc.org Company Website http://www.nlpc.org

March 01, 2024 10:00 AM Eastern Standard Time

Article thumbnail News Release

Unlocking the Secrets to Global Impact - Dr. Christina Rahm's Entrepreneurial Triumph

Deep Root Causes Ventures

Dr. Christina Rahm, a visionary entrepreneur, scientist, and philanthropist, is set to captivate audiences with her insights as a featured speaker at SXSW in Austin at the Grit Daily House on March 10. With over 30 years of experience, Dr. Rahm has emerged as a trailblazer in addressing global issues through her groundbreaking work in entrepreneurship and scientific innovation. Dr. Rahm, holding degrees in counseling, education, philosophy, and strategic sciences, stands as a well-rounded powerhouse committed to holistic well-being. Her roles as a scientist, inventor, artist, and philanthropist showcase her diverse skill set. Operating under DRC Ventures, Dr. Rahm leads 12 entities dedicated to humanity's betterment and aims to create positive global change. The Root Brands, Ella Pure Beauty, Rahm Roast, and her book " Cure the Causes: Live the Life You Want, Not the One Prescribed " exemplify her commitment to transformative ventures. The Root Brands products foster exceptional lifestyles, Ella Pure Beauty is an all-natural skincare line, and Rahm Roast is an all-natural clean coffee blend. Dr. Rahm is currently immersed in pioneering research in pharmaceutical, nutraceutical, biotechnology, and environmental sciences, contributing to global advancements. Dr. Rahm recently visited the Kennedy Center in Washington, D.C., where she shared her new book, “Roots of Military Science: Understanding the intersection of conflict, mental health and wellness”. Last winter, she was also on a European speaking tour, giving several presentations at prestigious events such as the World Economic Forum in Davos, Switzerland, and more. Dr. Rahm's speaking engagement at SXSW will continue to provide insights into her disruptive vision. Dr. Christina Rahm, Ph.D., is an internationally known scientific leader, spokesperson, and innovator in health and wellness whose approach revolves around dismantling root problems. A living embodiment of her motto, "the most important environment is yours," she travels the world presenting, lecturing, and educating the private and public sectors about the bold new world of nutraceuticals, wellness strategies, and environmental solutions, ultimately paving the way for the advancement of humanity. Contact Details R Public Relations Madison Baber +1 210-213-2426 madison@rprfirm.com Company Website https://www.drc-ventures.com/

February 29, 2024 03:44 PM Eastern Standard Time

Image
Article thumbnail News Release

For The First Time The US Is Set To Hit 2 Million New Cancer Cases: Theriva Biologics Presents Novel Solutions To The Deadliest Cancers

Benzinga

By Faith Ashmore, Benzinga A recent cancer study showed that the incidence rates of early-onset cancer “increased substantially” from 2010 to 2019. Breast cancer had the highest number of incident cases, and gastrointestinal cancers had the fastest-growing incidence rates among all early-onset cancers. The National Cancer Institute reports that colorectal cancer has become the leading cause of cancer-related deaths for Americans aged 20 to 59 years old. Doctors are expecting that in 2024, there will be more than 2 million new cases of cancer; this would be the first year the U.S. would cross that threshold, marking almost 5,500 cancer diagnoses a day. The increasing cancer incidence, especially among young people, is a big cause for concern in the medical community. Specifically, there is an increase in pancreatic cancer, which is expected to become the second-highest cause of cancer-associated deaths in 2030 in the U.S. Fortunately, fatality rates from cancer have steadily been on the decline for the past 30 years. This is largely due to better detection systems and advancements in treatment. Theriva Biologics (AMEX: TOVX) is one of the biotech companies that is helping push the envelope in cancer treatment. The company specializes in developing oncolytic viruses that are unique and highly differentiated. These viruses have been optimized for systemic administration and are designed to treat various types of cancer and make other cancer therapies more effective. They are optimized to be administered in combination with chemotherapy and immunotherapies, increasing access to the tumor and exposing the tumor to the immune system. The company’s lead drug candidate is VCN-01, which is a uniquely engineered human adenovirus 5. VCN-01 also expresses a protein named hyaluronidase that degrades the dense matrix surrounding human tumors, and this helps the action of chemotherapy and immunotherapies. The phase 1 clinical trials of VCN-01 have shown promising results for the treatment of several additional indications such as pancreatic cancer, retinoblastoma, head and neck squamous cell carcinoma (HNSCC) and colorectal cancer (CRC) in combination with chemotherapy and immunotherapies. The company's innovative Albumin Shield™ platform and oncolytic virus discovery engine have enabled the development of a distinct product pipeline that holds promise in the fight against cancer. Currently, the company is conducting a phase 2b clinical trial of its VCN-01 in combination with standard-of-care chemotherapy for first-line metastatic pancreatic cancer. Theriva Biologics is on track to complete enrollment into the VIRAGE Study by the first half of 2024. In the first quarter of 2024, a Drug Monitoring Committee (DMC) conducted a thorough safety review of VCN-01, ensuring that the drug meets the necessary criteria for continued development. By the second half of 2024, Theriva Biologics aims to perform an interim analysis of the data obtained from the VIRAGE Study. Theriva Biologics And Its Potential Markets By The Numbers The pancreatic cancer market’s size was estimated at $2.2 billion in 2022, and it's expected to grow at a CAGR of 13.6% between 2023 and 2032, reaching approximately $7.91 billion by 2032. Theriva Biologics seems well-positioned to excel in this space with its innovative VCN-01 drug candidate, with the potential to also serve other multi-billion dollar markets – such as head and neck cancer drugs, set to surpass $2.99 billion by 2030. Theriva Biologics reported $31.6 million in cash and short-term investment for Q3 2023. The company also increased research expenses to $4 million from $2.6 million a year ago while decreasing general and administrative expenses by 91% y-o-y. The company narrowed its net loss for the quarter from $4.49 million in Q3 2022 to $3.3 million in Q3 2023, and the basic loss per share for the quarter was $0.19 compared to $0.3 a year ago. Theriva Biologics currently has a market capitalization of about $8 million. The clinical-stage company’s innovative drug research might present a novel solution to extend the lives of those suffering from the deadliest of cancers, providing patients with new hope and improved outcomes. Featured photo by National Cancer Institute on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

February 29, 2024 08:25 AM Eastern Standard Time

Image
Article thumbnail News Release

MAIA Biotech Completes Enrollment For Phase 2 Trial Of Its Candidate THIO To Fight Non-Small Cell Lung Cancer

Benzinga

By Meg Flippin, Benzinga MAIA Biotechnology Inc. (AMEX: MAIA), the clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, completed enrollment for its phase 2 trial for THIO, its lead therapy to fight advanced non-small cell lung cancer or NSCLC. NSCLC is a disease in which cancer cells form in the tissues of the lung. It’s the most common form of lung cancer in the U.S., accounting for 81% of lung cancer diagnoses. The five-year survival rate for this type of cancer is 28%. THIO targets and compromises the function of telomeres, which play a key role in helping cancer cells live and spread. Telomeres are made from DNA sequences and proteins and sit at the end of chromosomes, capping and protecting them in the cell division progress. Telomeres can be regenerated with the support of telomerase, an enzyme present in the early stages of growth and development in humans and in very few cells of adults. Telomerase is present in nearly all cancers and is expressed in 80% of NSCLC tumors. Evaluating The Effectiveness THIO is recognized by telomerase, leading to the uncapping of telomeres and thus resulting in rapid tumor cell death. THIO induces telomerase-dependent telomeric DNA modification, DNA damage responses and selective cancer cell death. The phase 2 THIO-101 go-to-market clinical trial is designed to evaluate THIO sequenced with the immune checkpoint inhibitor cemiplimab (Libtayo®) in patients with NSCLC. In preclinical models in vivo, MAIA demonstrated that low doses of THIO followed by anti-PD-L1 or anti-PD1 therapy completely eliminated advanced tumors and produced cancer cell-specific memory to activate the immune system against the cancer cells after extended periods with no need for additional treatment. Enrollment Reached Ahead Of Schedule Earlier in February, the trial reached its enrollment target of 41 patients for the 180 mg dose. Initially, the trial was designed to test three dose levels but following the selection of 180 mg/cycle as the optimal dose in December all patients were enrolled at that dose level and trial enrollment was completed ahead of schedule, the company said in a press release. “Enrollment in our Phase 2 THIO-101 trial has been strong from the start. With excellent results across all doses and our selection of the optimal dose in December 2023, we enrolled the necessary number of patients in the Simon 2-stage design to achieve our trial endpoints earlier than expected,” said Vlad Vitoc, M.D., MAIA’s Chairman and Chief Executive Officer when announcing the enrollment results. “THIO-101 preliminary data has demonstrated unprecedented rates of disease control and response to date, and we look forward to the long-term efficacy results as we continue to monitor the enrolled patients in the upcoming months.” THIO Well Tolerated The main objectives of the trial are to evaluate the safety, tolerability and preliminary clinical efficacy of THIO in patients with advanced NSCLC who have experienced disease progression or relapse after initial treatments with an immune CPI alone or in combination with chemotherapy. THIO is currently being developed as a second or later line of treatment for NSCLC patients who have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors. MAIA Biotechnology said treatment with THIO followed by cemiplimab (Libtayo®) followed by THIO has been generally well tolerated to date in a heavily pre-treated population. “As the only direct telomere targeting agent currently undergoing clinical development in the field of cancer, we believe THIO holds a time-to-market advantage and strong potential to become a new standard of care for NSCLC,” said Vitoc. While THIO is currently being tested for NSCLC, telomerase is present in 85% to 95% of human cancers and contributes to the proliferation and reproductive immortality of cancer cells. As a result, the company is studying THIO in models of several tumor types with active telomerase, including rate indications in liver, colorectal and brain cancers. That could result in further use cases for MAIA’s lead treatment. Featured photo by National Cancer Institute on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

February 29, 2024 08:15 AM Eastern Standard Time

Image
Article thumbnail News Release

TeamBuilder's Innovative Staff Scheduling Solution Recognized in KLAS Insights Report

TeamBuilder

TeamBuilder, an innovative workforce management solution, has been featured in the latest insights report by KLAS, a renowned healthcare research firm. The report, titled "Emerging Insights Case Study on Workforce Management and Predictive Staff Scheduling through a Digital Platform," highlights TeamBuilder's pioneering approach to staff scheduling and its positive impact on healthcare organizations. Staff scheduling in healthcare has a unique set of challenges that can be exacerbated by provider volume and manual processes for clinical workflow management. These challenges can lead to problematic patient care and poor provider and staff experiences. The TeamBuilder solution, built specifically for ambulatory care, is intended to alleviate organizational pain points around staff scheduling by assessing the needs of day-to-day operations and offering predictive staff scheduling. Key findings from the case study include: Improved Operational Efficiency: TeamBuilder's predictive staff scheduling reduces administrative burdens and streamlines day-to-day operations, allowing healthcare organizations to focus on delivering quality patient care. Enhanced Staff Experience: Users of TeamBuilder's platform reported positive experiences, citing the ease of use, real-time notifications, and centralized communication features as key strengths. Positive Organizational Outcomes: TeamBuilder's digital schedule and recommendation engine drive positive outcomes, including workforce management optimization, reduced staffing costs, and improved visibility into staffing utilization across multiple sites. "What's been done traditionally around using staffing ratios often leads to chronic overstaffing and understaffing because they don't account for nuances like shifting patient volume, provider workflow and sites that answer phones," said David Howard, CEO and Founder of TeamBuilder. "What we've been able to do with TeamBuilder is to use data science to consume all of the nuances of a clinic's operating model and provide managers with the optimal schedule each week. No more paper. No more guessing." To read the full report, visit TeamBuilder — News. About TeamBuilder: TeamBuilder is a predictive staff scheduling platform built specifically for ambulatory care. Contact Details TeamBuilder Media info@teambuilder.io Company Website https://teambuilder.io/

February 29, 2024 08:00 AM Eastern Standard Time

12345 ... 246